PHL-METHYLPHENIDATE 20 MG
METHYLPHENIDATE HYDROCHLORIDE : 20 MG · DIN 02126486 · PHARMEL INC
Health Canada status: CANCELLED POST MARKET
What is PHL-METHYLPHENIDATE?
PHL-METHYLPHENIDATE 20 MG contains METHYLPHENIDATE HYDROCHLORIDE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 02126486, held by PHARMEL INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 21-Apr-2003. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What else is PHL-METHYLPHENIDATE called?
The same molecule, METHYLPHENIDATE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Concerta | Latin | Australia, South Africa |
| Ritalin La | Latin | Australia, South Africa |
| ATTORA LA | Latin | Australia |
| Rubifen LA | Latin | Australia |
| Methylphenidate Sandoz XR | Latin | Australia |
| Methylphenidate XR ARX | Latin | Australia |
| METHYLPHENIDATE-TEVA XR | Latin | Australia |
| Quillivant XR | Latin | Saudi Arabia |
| Concentia | Latin | Saudi Arabia |
| Concerta (Switzerland) | Latin | Australia |
| Atenza (Spain) | Latin | Australia |
| Adaphen | Latin | South Africa |
| Adaphen Xl | Latin | South Africa |
| Artige | Latin | Australia |
| Concerta® | Latin | South Africa |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02126486 |
|---|---|
| Brand name | PHL-METHYLPHENIDATE |
| Generic / active ingredient | METHYLPHENIDATE HYDROCHLORIDE : 20 MG |
| Manufacturer | PHARMEL INC |
| Strength | 20 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | CONTROLLED DRUGS (CDSA III) |
| ATC code | N06BA04 METHYLPHENIDATE |
| AHFS class | 28:20.32 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 21-Apr-2003 |
| Original market date | 2003-04-21 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02126486 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2126486 |
| Brand name | PHL-METHYLPHENIDATE |
| Active ingredient / INN | METHYLPHENIDATE HYDROCHLORIDE : 20 MG |
| ATC code | N06BA04 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N06 |
| AHFS class | 28:20.32 |
| Health Canada schedule | CONTROLLED DRUGS (CDSA III) |
| Biosimilar biologic | No |
| Market authorization holder | PHARMEL INC |
Which pack is which?
| Strength on the label | 20 MG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
What can be used instead?
Other Canadian products sharing ATC code N06BA04 METHYLPHENIDATE. 55 of 103 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT METHYLPHENIDATE ER | 18 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441934 |
| ACT METHYLPHENIDATE ER | 27 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441942 |
| ACT METHYLPHENIDATE ER | 36 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441950 |
| ACT METHYLPHENIDATE ER | 54 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441969 |
| APO-METHYLPHENIDATE | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02249324 |
| APO-METHYLPHENIDATE | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02249332 |
| APO-METHYLPHENIDATE | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02273950 |
| APO-METHYLPHENIDATE ER | 18 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452731 |
| APO-METHYLPHENIDATE ER | 27 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452758 |
| APO-METHYLPHENIDATE ER | 36 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452766 |
Who else supplies METHYLPHENIDATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METHYLPHENIDATE appears in 923 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does METHYLPHENIDATE cost around the world?
METHYLPHENIDATE is listed on 6 national price registers Nexara tracks, across 131 pack listings published on 6 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| United States | acquisition | 12 | 61 | 03 Sep 2026 |
| Australia | ex-manufacturer | 12 | 39 | 08 Sep 2026 |
| South Africa | single exit price | 13 | 16 | 01 Sep 2026 |
| Saudi Arabia | public | 5 | 10 | 01 Sep 2026 |
| United Kingdom | hospital | 3 | 3 | 31 Aug 2026 |
| Greece | producer price (ex-factory) | 2 | 2 | 03 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.